$10.03
-0.04-0.39%
Last update: 10:14 AM
15 minutes delayed
Comments
Loading...
Inovio Pharmaceuticals
INONASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Inovio Pharmaceuticals (NASDAQ:INO) Stock, Analyst Ratings, Price Targets, Forecasts
Inovio Pharmaceuticals Inc has a consensus price target of $14.83 based on the ratings of 7 analysts. The high is $40 issued by Oppenheimer on March 8, 2024. The low is $1 issued by JMP Securities on January 4, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Stephens & Co., and Oppenheimer on July 15, 2024, May 14, 2024, and March 8, 2024, respectively. With an average price target of $25 between HC Wainwright & Co., Stephens & Co., and Oppenheimer, there's an implied 148.26% upside for Inovio Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Stephens & Co.
Oppenheimer
RBC Capital
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Inovio Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/15/2024 | Buy Now | 48.96% | HC Wainwright & Co. | Raghuram Selvaraju | $15 → $15 | Reiterates | Neutral → Neutral | Get Alert |
| 05/14/2024 | Buy Now | 98.61% | Stephens & Co. | Sudan Loganathan | → $20 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 297.22% | Oppenheimer | Hartaj Singh | $40 → $40 | Maintains | Outperform | Get Alert |
| 03/07/2024 | Buy Now | 9.24% | RBC Capital | Gregory Renza | → $11 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/25/2024 | Buy Now | -60.28% | Oppenheimer | Hartaj Singh | → $4 | Upgrade | Perform → Outperform | Get Alert |
| 01/04/2024 | Buy Now | -90.07% | JMP Securities | Roy Buchanan | → $12 | Initiates | → Market Outperform | Get Alert |
| 05/11/2023 | Buy Now | -80.14% | RBC Capital | Gregory Renza | → $24 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/02/2023 | Buy Now | -80.14% | RBC Capital | Gregory Renza | $36 → $24 | Maintains | Sector Perform | Get Alert |
| 11/09/2022 | Buy Now | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 11/01/2022 | Buy Now | -80.14% | B of A Securities | Geoff Meacham | → $24 | Downgrade | Neutral → Underperform | Get Alert |
| 08/10/2022 | Buy Now | -70.21% | RBC Capital | Gregory Renza | $48 → $36 | Maintains | Sector Perform | Get Alert |
| 05/11/2022 | Buy Now | — | Oppenheimer | Hartaj Singh | — | Downgrade | Outperform → Perform | Get Alert |
| 03/02/2022 | Buy Now | -50.35% | RBC Capital | Gregory Renza | $72 → $60 | Maintains | Sector Perform | Get Alert |
| 01/21/2022 | Buy Now | -0.7% | B of A Securities | Geoff Meacham | $96 → $120 | Upgrade | Underperform → Neutral | Get Alert |
| 11/01/2021 | Buy Now | -40.42% | RBC Capital | Gregory Renza | $84 → $72 | Maintains | Sector Perform | Get Alert |
| 09/10/2021 | Buy Now | -20.56% | B of A Securities | Geoff Meacham | $108 → $96 | Downgrade | Neutral → Underperform | Get Alert |
FAQ
What is the target price for Inovio Pharmaceuticals (INO) stock?
The latest price target for Inovio Pharmaceuticals (NASDAQ:INO) was reported by HC Wainwright & Co. on July 15, 2024. The analyst firm set a price target for $15.00 expecting INO to rise to within 12 months (a possible 49.53% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inovio Pharmaceuticals (INO)?
The latest analyst rating for Inovio Pharmaceuticals (NASDAQ:INO) was provided by HC Wainwright & Co., and Inovio Pharmaceuticals reiterated their neutral rating.
When was the last upgrade for Inovio Pharmaceuticals (INO)?
The last upgrade for Inovio Pharmaceuticals Inc happened on January 25, 2024 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Inovio Pharmaceuticals Inc.
When was the last downgrade for Inovio Pharmaceuticals (INO)?
The last downgrade for Inovio Pharmaceuticals Inc happened on November 9, 2022 when Maxim Group changed their price target from N/A to N/A for Inovio Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Inovio Pharmaceuticals (INO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inovio Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inovio Pharmaceuticals was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.
Is the Analyst Rating Inovio Pharmaceuticals (INO) correct?
While ratings are subjective and will change, the latest Inovio Pharmaceuticals (INO) rating was a reiterated with a price target of $15.00 to $15.00. The current price Inovio Pharmaceuticals (INO) is trading at is $10.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.